Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patient With Chronic HBV

PHASE3TerminatedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

June 30, 2003

Study Completion Date

November 30, 2004

Conditions
Hepatitis B
Interventions
DRUG

clevudine

Trial Locations (33)

Unknown

St. Mercy's Hospital, Bupyoung-dong

Pusan Paik Hospital, Gaegeum-dong

Kangbuk Samsung Hospital, Pyoung-dong

Keimyumg University Dongsan Medical Center, Jung-gu

Kyungpook National University Medical Hospital, Jung-gu

Chonnam National University Hospital, Hak-1-dong

Korea University Guro Hospital, Seoul

Wonkwang University Hospital, Iksan

Chonbuk National University Hospital, Jeonju

Chungnam National University Hospital, Daesadong

Inha University Hospital, Sinhŭng-dong

Seoul Asan Medical Center, Pungnap-dong

Yongdong Severance Hospital, Togok-tong

National Cancer Center, Ilsan-gu

St. Holly Family Mary's Hospital, Pucheon

Pochon CHA University Hospital, Seongnam-gu

Yeungnam University Medical Center, Dae Myoung-dong

Korea Cancer Center Hospital, Gongneungdong

Nowon Eulji Hospital, Hagyeil-tong

St. Vincent's Hospital, Chi-dong

Pusan National University Hospital, Ami-dong

Kosin Medical Center, Amnam-dong

KangNam St. Mary's Hospital, Banpo-dong

Severance Hospital, Shinchon- Dong

Seoul Paik Hospital, Jeo-dong

Samsung Medical Center, Ilwon-dong

Korea University Anam Hospital, Anam-dong

Ehwa Womans University Mokdong Hospital, Mokdong

Kangnam Sacred Heart Hospital, Daelim-dong

Soon Chun Hyang University Hospital, Hannam-dong

St. Mary's Hospital, Seoul

Gil Medical Center, Incheon

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Bukwang Pharmaceutical

INDUSTRY

NCT00313287 - Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patient With Chronic HBV | Biotech Hunter | Biotech Hunter